Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis

Neurology. 2004 Dec 28;63(12):2381-3. doi: 10.1212/01.wnl.0000147259.34163.33.

Abstract

Antibodies against native glycosylated myelin-oligodendrocyte-glycoprotein (MOG) were measured by ELISA in patients with multiple sclerosis (MS) and controls. Anti-MOG IgM antibodies were elevated during the first demyelinating event. Higher MOG-specific IgG antibodies were found in patients during relapses and in secondary chronic progressive MS compared to patients in remission and healthy controls. Antibodies against native MOG may be a potential biomarker for MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Animals
  • Antibody Specificity
  • Autoantibodies / blood
  • Autoantibodies / immunology*
  • Demyelinating Diseases
  • Female
  • Glycosylation
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology*
  • Immunoglobulin M / blood
  • Immunoglobulin M / immunology*
  • Male
  • Mice
  • Middle Aged
  • Multiple Sclerosis, Chronic Progressive / immunology*
  • Multiple Sclerosis, Relapsing-Remitting / immunology*
  • Myelin Proteins
  • Myelin-Associated Glycoprotein / chemistry
  • Myelin-Associated Glycoprotein / immunology*
  • Myelin-Associated Glycoprotein / isolation & purification
  • Myelin-Oligodendrocyte Glycoprotein
  • Protein Processing, Post-Translational*

Substances

  • Autoantibodies
  • Immunoglobulin G
  • Immunoglobulin M
  • MOG protein, human
  • Mog protein, mouse
  • Myelin Proteins
  • Myelin-Associated Glycoprotein
  • Myelin-Oligodendrocyte Glycoprotein